-
公开(公告)号：EP1385870A2
公开(公告)日：2004-02-04
申请号：EP01954764.5
申请日：2001-07-19
发明人： SAKSENA, Anil, K. , GIRIJAVALLABHAN, Viyyoor, Moopil , LOVEY, Raymond, G. , JAO, Edwin, E. , BENNETT, Frank , MC CORMICK, Jinping, L. , WANG, Haiyan , PIKE, Russell, E. , BOGEN, Stephane, L. , CHAN, Tin-Yau , LIU, Yi-Tsung , ZHU, Zhaoning , NJOROGE, F., George , ARASAPPAN, Ashok , PAREKH, Tejal, N. , GANGULY, Ashit, K. , CHEN, Kevin, X. , VENKATRAMAN, Srikanth , VACCARO, Henry, A. , PINTO, Patrick A. , SANTHANAM, Bama , WU, Wanli , HENDRATA, Siska , HUANG, Yuhua , KEMP, Scott Jeffrey , LEVY, ODILE ESTHER , LIM-WILBY, Marguetita , TAMURA, Susan Y.
IPC分类号： C07K1/00
CPC分类号： C07K5/0202 , A61K38/00 , C07K5/0812 , C07K5/0827 , C07K7/02
摘要： The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease.
-
2.发明公开
公开(公告)号：EP1301528A2
公开(公告)日：2003-04-16
申请号：EP01959046.2
申请日：2001-07-19
发明人： SAKSENA, Anil, K. , GIRIJAVALLABHAN, Viyyoor, Moopil , LOVEY, Raymond, G. , JAO, Edwin, E. , BENNETT, Frank , MCCORMICK, Jinping , WANG, Haiyan , PIKE, Russell, E. , BOGEN, Stephane, L. , LIU, Yi-Tsung , ARASAPPAN, Ashok , PAREKH, Tejal , PINTO, Patrick, A. , NJOROGE, F., George , GANGULY, Ashit, K. , BRUNCK, Terence, K. , KEMP, Scott, Jeffrey , LEVY, Odile, Esther , LIM-WILBY, Marguerita
摘要： The present invention discloses novel peptide compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such peptides as well as methods of using them to treat disorders associated with the HCV protease.
摘要翻译： 本发明公开了具有HCV蛋白酶抑制活性的新型肽化合物以及制备该化合物的方法。 在另一个实施方案中，本发明公开了包含此类肽的药物组合物以及使用它们治疗与HCV蛋白酶相关的病症的方法。
-
3.发明公开NOVEL PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS 审中-公开NEW肽NS3蛋白酶抑制剂SERIN丙型肝炎病毒的
公开(公告)号：EP1303487A1
公开(公告)日：2003-04-23
申请号：EP01959041.3
申请日：2001-07-19
发明人： SAKESENA, Anil K. , GIRIJAVALLABHAN, Viyyoor, Moopil , BOGEN, Stephane, L. , LOVEY, Raymond, G. , JAO, Edwin, E. , BENNETT, Frank , MC CORMICK, Jinping, L. , WANG, Haiyan , PIKE, Russell, E. , LIU, Yi-Tsung , CHAN, Tin-Yau , ZHU, Zhaoning , ARASAPPAN, Ashok , CHEN, Kevin, X. , VENKATRAMAN, Srikanth , PAREKH, Tejal, N. , PINTO, Patrick, A. , SANTHANAM, Bama , NJOROGE, F., George , GANGULY, Ashit K. , VACCARO, Henry A. , KEMP, Scott Jeffrey , LEVY, Odile Esther , LIM-WILBY, Marguerita , TAMURA, Susan Y.
IPC分类号： C07D209/02 , C07D211/04 , C07D233/56 , C07D317/10 , C07D319/04 , C07D339/02 , C07D339/08 , C07C229/00 , C07C233/05 , C07C271/08 , C07C271/32 , A61K31/16 , A61K31/27 , A61K31/195 , A61K31/357 , A61K31/385 , A61K31/403 , A61K31/445 , A61K31/4164
CPC分类号： C07K7/06 , A61K31/16 , A61K31/195 , A61K31/27 , A61K31/357 , A61K31/385 , A61K31/403 , A61K31/4164 , A61K31/445 , A61K38/05 , C07C205/51 , C07K5/101 , C07K7/02 , A61K2300/00
摘要： The present invention discloses novel peptide compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease.
-
4.发明公开RIBAVIRIN-INTERFERON ALFA COMBINATION THERAPY FOR ERADICATING DETECTABLE HCV-RNA IN PATIENTS HAVING CHRONIC HEPATITIS C INFECTION 审中-公开利巴韦林干扰素-α-组合销毁检测的HCV-RNA慢性丙型肝炎治疗的感染的患者
公开(公告)号：EP1282632A1
公开(公告)日：2003-02-12
申请号：EP01928662.4
申请日：2001-04-18
申请人： SCHERING CORPORATION
发明人： GANGULY, Ashit, K. , MCCORMICK, Jinping , LOVEY, Raymond, G. , BENNETT, Frank , SAKSENA, Anil, K. , GIRIJAVALLABHAN, Viyyoor, M.
IPC分类号： C07H19/056 , A61K31/7056 , A61P31/12
CPC分类号： C07H19/056 , Y10S514/894
摘要： Ribavirin derivatives represented by the formula (II), pharmaceutical compositions containing them as well as the use of the ribavirin derivatives represented by the formula (II) for the preparation of a medicament for the treatment of susceptible viral infections, for example, chronic hepatitis C infections administrating, the ribavirin derivatives being represented by formula (II) are disclosed.
-
5.发明授权
公开(公告)号：EP1481000B1
公开(公告)日：2010-06-02
申请号：EP03731956.3
申请日：2003-01-16
发明人： SAKSENA, Anil, K. , GIRIJAVALLABHN, Viyyoor, M. , LOVEY, Raymond, G. , JAO, Edwin , BENNETT, Frank , MC CORMICK, Jinping, L. , WANG, Haiyan , PIKE, Russell, E. , BOGEN, Stephane, L. , CHAN, Tin-Yau , LIU, Yi-Tsung , ZHU, Zhaoning , NJOROGE, George, F. , ARASAPPAN, Ashok , PAREKH, Tejal , GANGULY, Ashit, K. , CHEN, Kevin, X. , VENKATRAMAN, Srikanth , VACCARO, Henry, A. , PINTO, Patrick A. , SANTHANAM, Bama , KEMP, Scott Jeffrey , LEVY, Odile Esther , LIM-WILBY, Marguerita , TAMURA, Susan Y. , WU, Wanli , HENDRATA, Siska , HUANG, Yuhua , WONG, Jesse K. , NAIR, Latha G.
CPC分类号： C07K5/0804 , A61K38/00 , C07K5/0202 , C07K5/0812 , C07K5/0827 , C07K7/02
摘要： The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease.
-
6.发明公开PROLINE COMPOUNDS AS NS3-SERINE PROTEASE INHIBITORS FOR USE IN TREATMENT OF HEPATITIS C VIRUS INFECTION 有权脯氨酸AS NS3丝氨酸蛋白酶抑制剂，其用于丙型肝炎病毒感染的控制
公开(公告)号：EP1467989A1
公开(公告)日：2004-10-20
申请号：EP03705843.5
申请日：2003-01-21
申请人： SCHERING CORPORATION
发明人： ARASAPPAN, Ashok , BENNETT, Frank , BOGEN, Stephane, L. , CHEN, Kevin, X. , JAO, Edwin , LIU, Yi-Tsung , LOVEY, Raymond, G. , MADISON, Vincent, S. , NAIR, Latha, G. , NJOROGE, F., George , SAKSENA, Anil, K. , SANNIGRAHI, Mousumi , VENKATRAMAN, Srikanth , GIRIJAVALLABHAN, Viyyoor, M.
IPC分类号： C07D403/12 , A61K38/55 , A61P31/12
CPC分类号： C07D207/27 , C07D207/16 , C07D209/08 , C07D209/42 , C07D211/26 , C07D211/34 , C07D211/70 , C07D213/75 , C07D217/26 , C07D233/68 , C07D243/12 , C07D253/06 , C07D271/06 , C07D277/06 , C07D277/46 , C07D277/56 , C07D295/15 , C07D307/68 , C07D317/58 , C07D335/10 , C07D401/04 , C07D401/14 , C07D403/12 , C07D405/06 , C07D405/12
摘要： The present invention discloses novel compounds of Formula I which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease.
-
公开(公告)号：EP0773941B1
公开(公告)日：2003-05-14
申请号：EP96916574.5
申请日：1996-05-30
申请人： SCHERING CORPORATION
发明人： SAKSENA, Anil, K. , GIRIJAVALLABHAN, Viyyoor, M. , LOVEY, Raymond, G. , PIKE, Russell, E. , WANG, Haiyan , LIU, Yi-Tsung , GANGULY, Ashit, K. , BENNETT, Frank
IPC分类号： C07D405/14 , A61K31/41
CPC分类号： C07D249/08 , C07D231/12 , C07D233/56
摘要： A compound represented by formula (I), wherein X is independently both F or both Cl or one X is independently F and the other is independently Cl; R1 is a straight or branched chain (C4 to C5) alkyl group substituted by one or two amino acid ester grou ps convertible in vivo into a hydroxy group or a pharmaceutically acceptable salt thereof and pharmaceutical compositions thereof useful for treating and/or preventing fungal infections are disclosed.
-
公开(公告)号：EP0610377B1
公开(公告)日：2001-01-24
申请号：EP92923060.5
申请日：1992-10-28
申请人： SCHERING CORPORATION
IPC分类号： C07D405/06 , C07D249/12 , C07D295/08 , C07D207/09 , C07D405/14 , A61K31/41
CPC分类号： C07D295/096 , C07D207/09 , C07D231/12 , C07D233/56 , C07D249/08 , C07D249/12
摘要： An antifungal compound represented by formula (I), wherein X is independently both F or both Cl or one X is F and the other is Cl; Y = (a), (b), (c), (d), (e), (f) or (g); R' = (C1-C10)alkyl, (C2-C10)alkenyl, (C2-C10)alkynyl, (C3-C8)cycloalkyl or CH2R?2; R2 = (C¿1-C3)perhaloalkyl, CO2R3, *CH(OR4)CH2OR4 or CH¿2?N(R?5); R3¿ = lower alkyl or H; R4 = R3 or (CH¿2?)2OR?3; R5¿ = lower alkyl; Z = H or (C¿1?-C5)alkanoyl and the carbons with the asterisks (*) have the R or S absolute configuration; or a pharmaceutically acceptable salt thereof as well as pharmaceutical compositions containing them and a method of treating or preventing fungal infections in mammals using them are disclosed.
-
公开(公告)号：EP0736030B1
公开(公告)日：2001-08-29
申请号：EP95906620.0
申请日：1994-12-20
申请人： SCHERING CORPORATION
发明人： SAKSENA, Anil, K. , GIRIJAVALLABHAN, Viyyoor, M. , LOVEY, Raymond, G. , PIKE, Russell, E. , WANG, Haiyan , LIU, Yi-Tsung , GANGULY, Ashit, K. , BENNETT, Frank
IPC分类号： C07D521/00 , C07F9/6558 , A61K31/495 , A61K31/66
CPC分类号： C07D249/08 , C07D231/12 , C07D233/56 , C07F9/65586
摘要： A compound represented by formula (I) wherein X is independently both F or both Cl or one X is independently F and the other is independently Cl; R1 is a straight or branched chain (C3 to C8) alkyl group substituted by one or two hydroxy moieties, an ether or ester (e.g., a polyestherester or phosphate ester) thereof a pharmaceutically acceptable salt thereof and pharmaceutical compositions thereof useful for treating and/or preventing fungal infections are disclosed.
-
10.发明公开RIBAVIRIN-INTERFERON ALFA COMBINATION THERAPY FOR ERADICATING DETECTABLE HCV-RNA IN PATIENTS HAVING CHRONIC HEPATITIS C INFECTION 有权RIBAVIRIN-INTERFERON ALFA联合治疗对慢性丙型肝炎病毒感染患者可检测HCV-RNA的检测
公开(公告)号：EP1121369A1
公开(公告)日：2001-08-08
申请号：EP99970662.5
申请日：1999-10-14
申请人： SCHERING CORPORATION
发明人： GANGULY, Ashit, K. , MCCORMICK, Jinping , LOVEY, Raymond, G. , BENNETT, Frank , SAKSENA, Anil, K. , GIRIJAVALLABHAN, Viyyoor, M.
IPC分类号： C07H19/056 , A61K31/70
CPC分类号： C07H19/056
摘要： A method for treating a patient having chronic hepatitis C infection to eradicate detectable HCV-RNA involving a combination therapy using a therapeutically effective amount of ribavirin derivative of formula (I) and a therapeutically effective amount of interferon-alpha for a time period of from 20 up to 80 weeks.
摘要翻译： 一种治疗患有慢性丙型肝炎感染的患者以根除可检测的HCV-RNA的方法，涉及组合疗法，使用治疗有效量的式（I）的利巴韦林衍生物和治疗有效量的干扰素-α，时间为20 长达80周。
-
-
-
-
-
-
-
-
-
搜索结果
24 条记录 (耗时 0.022 秒)
